Johnson & Johnson received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an ablation catheter that delivers both radiofrequency and pulsed field energy through a single device integrated with the CARTO mapping ecosystem. U.S. procedures are set to begin following a phased commercial rollout this summer. The dual-energy, single-catheter approach could deepen Johnson & Johnson's position in advanced electrophysiology by simplifying physician workflows and broadening the range of treatable patients. Cardiovascular MedTech generated almost US$9.0 billion of sales in 2025, and management plans at least one new pulsed field ablation catheter each year, with this approval serving as an early example of that roadmap.
Johnson & JohnsonFDA approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform enables commercial launch and strengthens electrophysiology position.